20 Jul 2020 11:35
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
REDX PHARMA PLC
("Redx" or "the Company")
Result of General Meeting
Alderley Park, 20 July 2020 Redx Pharma (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that at the General Meeting of the Company held earlier today, all resolutions put to the meeting were duly passed.
The table below sets out the details of the votes put to shareholders:
Resolution number | Resolution name | Number of votes for & discretionary | % of votes for & discretionary | Number of votes against | % of votes against | % votes withheld | Total votes cast (including withheld) |
1 | Allot shares | 175,305,377 | 99.99% | 11,514 | 0.01% | 0.00% | 175,321,878 |
2 | Pre-emption rights | 175,305,377 | 99.99% | 11,514 | 0.01% | 0.00% | 175,321,878 |
3 | Increase borrowing powers | 175,306,863 | 99.99% | 10,028 | 0.01% | 0.00% | 175,321,878 |
Following the passing of the resolutions the Company intends to drawdown the Loan in a single tranche as soon as practicable.
Furthermore, as a consequence of the passing of the resolutions, together with the subscription agreement with Sofinnova Partners (through its investment fund Sofinnova Crossover 1 SLP) ("Sofinnova") as announced on 30 June 2020, 5,238,710 new ordinary shares will be issued and allotted to Sofinnova. Following admission, expected to take place on 21 July 2020, of the 5,238,710 new ordinary shares, the Company confirms that, it will have 195,247,413 ordinary shares of 1p each with voting rights in issue. The Company holds no ordinary shares in treasury. Accordingly, the total number of voting rights in Redx will be 195,247,413 Which may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:
Redx Pharma Plc | T: +44 1625 469 920 |
Lisa Anson, Chief Executive Officer |
|
James Mead, Chief Financial Officer |
|
|
|
SPARK Advisory Partners (Nominated Advisor) | T: +44 20 3368 3550 |
Matt Davis/Henry Todd |
|
|
|
WG Partners LLP (Joint Broker and Financial Adviser) | T: +44 20 3705 9330 |
Claes Spång/Chris Lee/David Wilson |
|
|
|
FTI Consulting | T: +44 20 3727 1000 |
Simon Conway/Ciara Martin |
|
About Redx Pharma Plc
Redx is a UK biotechnology Group whose shares are traded on AIM (AIM:REDX). Redx is focused on creating and developing first, or potentially best in class drugs, in specific areas of cancer and fibrosis that address significant unmet medical need. Redx has an in-house discovery team with proven world-class chemistry capabilities.
If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/